More Videos
|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- The Rising Mountain of Debt May Be the Next Crisis
- Latvian Banker Taking Souls as Collateral
- SEC May Reinstate Rules for Short-Selling Stocks
- Cuddle Parties Heat Up
- Alaska Governor Sarah Palin Will Resign
- A Goldman Trading Scandal?
- The Worst Expected 2010 State Budget Gaps
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
- A Goldman Trading Scandal?
- Top Videos: From the Black Swan to the Bond King
- Obama Plan Would Trim Back Financial Powerhouses
- Biden: 'We Misread How Bad The Economy Was'
- FedEx Sees Signs of a Turnaround: Report
- Property Tax Appeals Take Toll on Governments
- Chrysler Names Remaining Directors to New Board
- Car Dealer Determined To Fight Chrysler Over Franchise
- 'Ice Age' Heats Up Worldwide Box Office
PHARMA'S MARKET VIDEO
RSS FEED
Text Size 
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
Although Alkermes could presumably find another corporate partner to try to rescue its "AIR Insulin" product, MannKind [MNKD
Loading...
()
] is the only company left still actively developing an inhalable form of diabetic insulin. And so this afternoon, MannKind put out a press release
with the header, "MannKind Corporation Response to Recent Market Events", reaffirming its commitment to the device. "MannKind is absolutely commited to the continued development of its lead development product, Technosphere Insulin," the statement says.
The release goes on in detail about the product's safety and efficacy. The company is testing Technosphere on more than 5,000 people and more than 2,000 of them are in a two-year study to specifically measure the impact, if any, on lung function.
Mr. Mann is putting his money where his mouth is and has reportedly invested about a billion dollars from his own bank account in the device. And the company says it has the wherewithal to see it through.
"Currently, MannKind has sufficient financial resources to fund these programs and others (Technosphere and other development pipeline products) through the end of 2009."
And despite the fact that drug giants Lilly [LLY
Loading...
()
] , Pfizer [PFE
Loading...
()
] and NovoNordisk [NVO
Loading...
()
] have all recently gotten out of the inhalable insulin business the release says: "It is MannKind's intention to bring these treatments to patients in collaboration with a leading pharmaceutical partner who shares a commitment to improving the lives of people with diabetes and who understands the difference between MannKind's products and other diabetes therapies on the market today."
MannKind still closed at a new low of $4.99, but well above its intra-day low of $4.25.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes